Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

Gepubliceerd in: Child Psychiatry & Human Development 5/2017

03-11-2016 | Original Article

Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive–Compulsive Disorder in Childhood

Auteurs: Ulku Akyol Ardic, Eyup Sabri Ercan, Ayse Kutlu, Deniz Yuce, Melis Ipci, Sevim Berrin Inci

Gepubliceerd in: Child Psychiatry & Human Development | Uitgave 5/2017

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

The aim of this study is to evaluate the aripiprazole augmentation of selective seratonine reuptake inhibitors (SSRIs) in children and adolescents with treatment-resistant OCD. Forty-eight children and adolescents (14 girls, 34 boys), who are non-responders to treatment with at least two types of SSRIs and CBT, were administered a 12-week of augmentation. Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS), and Clinical Global Impression-Severity and Improvement (CGI-S and CGI-I) sub-scales were used for evaluation of the treatment outcomes. The results showed that total CY-BOCS scores were decreased from 33.3 ± 7.5 to 11.7 ± 9.3 (p < 0.001), CGI-S scores decreased from 6.3 ± 0.9 to 2.7 ± 1.6 (p < 0.001), and CGI-I scores improved from 4.3 ± 0.6 to 2.2 ± 1.1 (p < 0.001). Sensitivity analyses in 29 patients without SSRI dose escalation along with aripiprazole augmentation have also revealed that improvement effect was still significant, and CY-BOCS scores were improved from 34.2 ± 7.9 to 13 ± 10.3, CGI-S improved from 6.4 ± 1.0 to 3.0 ± 1.7, and CGI-I improved from 4.4 ± 1.0 to 2.3 ± 1.1 (p < 0.001 for all). Analyses revealed that a significant clinical improvement has been observed with aripiprazole augmentation. Aripiprazole augmentation of SSRIs is a promising strategy in the management of treatment-refractory OCD children and adolescents.
Literatuur
3.
go back to reference Hollander E et al (2010) Quality of life outcomes in patients with obsessive–compulsive disorder: relationship to treatment response and symptom relapse. J Clin Psychiatry 71(6):784–792 CrossRefPubMed Hollander E et al (2010) Quality of life outcomes in patients with obsessive–compulsive disorder: relationship to treatment response and symptom relapse. J Clin Psychiatry 71(6):784–792 CrossRefPubMed
5.
go back to reference Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet 349(9064):1498–1504 CrossRefPubMed Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990–2020: global burden of disease study. Lancet 349(9064):1498–1504 CrossRefPubMed
6.
go back to reference Flament MF et al (1988) Obsessive compulsive disorder in adolescence: an epidemiological study. J Am Acad Child Adolesc Psychiatry 27(6):764–771 CrossRefPubMed Flament MF et al (1988) Obsessive compulsive disorder in adolescence: an epidemiological study. J Am Acad Child Adolesc Psychiatry 27(6):764–771 CrossRefPubMed
7.
go back to reference Douglass HM et al (1995) Obsessive–compulsive disorder in a birth cohort of 18-year-olds: prevalence and predictors. J Am Acad Child Adolesc Psychiatry 34(11):1424–1431 CrossRefPubMed Douglass HM et al (1995) Obsessive–compulsive disorder in a birth cohort of 18-year-olds: prevalence and predictors. J Am Acad Child Adolesc Psychiatry 34(11):1424–1431 CrossRefPubMed
8.
go back to reference Heyman I et al (2001) Prevalence of obsessive–compulsive disorder in the British nationwide survey of child mental health. Br J Psychiatry 179:324–329 CrossRefPubMed Heyman I et al (2001) Prevalence of obsessive–compulsive disorder in the British nationwide survey of child mental health. Br J Psychiatry 179:324–329 CrossRefPubMed
9.
go back to reference Stewart SE et al (2004) Long-term outcome of pediatric obsessive–compulsive disorder: a meta-analysis and qualitative review of the literature. Acta Psychiatr Scand 110(1):4–13 CrossRefPubMed Stewart SE et al (2004) Long-term outcome of pediatric obsessive–compulsive disorder: a meta-analysis and qualitative review of the literature. Acta Psychiatr Scand 110(1):4–13 CrossRefPubMed
10.
go back to reference Micali N et al (2010) Long-term outcomes of obsessive–compulsive disorder: follow-up of 142 children and adolescents. Br J Psychiatry 197(2):128–134 CrossRefPubMed Micali N et al (2010) Long-term outcomes of obsessive–compulsive disorder: follow-up of 142 children and adolescents. Br J Psychiatry 197(2):128–134 CrossRefPubMed
11.
go back to reference Piacentini J et al. (2003) Functional impairment in children and adolescents with obsessive–compulsive disorder. J Child Adolesc Psychopharmacol 13(Suppl 1):S61–S69 CrossRefPubMed Piacentini J et al. (2003) Functional impairment in children and adolescents with obsessive–compulsive disorder. J Child Adolesc Psychopharmacol 13(Suppl 1):S61–S69 CrossRefPubMed
12.
go back to reference Arumugham SS, Reddy YC (2014) Commonly asked questions in the treatment of obsessive–compulsive disorder. Expert Rev Neurother 14(2):151–163 CrossRefPubMed Arumugham SS, Reddy YC (2014) Commonly asked questions in the treatment of obsessive–compulsive disorder. Expert Rev Neurother 14(2):151–163 CrossRefPubMed
13.
go back to reference Bloch MH, Storch EA (2015) Assessment and management of treatment-refractory obsessive–compulsive disorder in children. J Am Acad Child Adolesc Psychiatry 54(4):251–262 CrossRefPubMedPubMedCentral Bloch MH, Storch EA (2015) Assessment and management of treatment-refractory obsessive–compulsive disorder in children. J Am Acad Child Adolesc Psychiatry 54(4):251–262 CrossRefPubMedPubMedCentral
14.
go back to reference Franklin ME et al (2015) Cognitive-behavioral therapy for pediatric obsessive–compulsive disorder: empirical review and clinical recommendations. Psychiatry Res 227(1):78–92 CrossRefPubMed Franklin ME et al (2015) Cognitive-behavioral therapy for pediatric obsessive–compulsive disorder: empirical review and clinical recommendations. Psychiatry Res 227(1):78–92 CrossRefPubMed
15.
go back to reference Bridge JA et al (2007) Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. J Am Med Assoc 297(15):1683–1696 CrossRef Bridge JA et al (2007) Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. J Am Med Assoc 297(15):1683–1696 CrossRef
16.
go back to reference Arumugham SS, Reddy JY (2013) Augmentation strategies in obsessive–compulsive disorder. Expert Rev Neurother 13(2):187–202 ( quiz 203) CrossRefPubMed Arumugham SS, Reddy JY (2013) Augmentation strategies in obsessive–compulsive disorder. Expert Rev Neurother 13(2):187–202 ( quiz 203) CrossRefPubMed
17.
go back to reference Abudy A, Juven-Wetzler A, Zohar J (2011) Pharmacological management of treatment-resistant obsessive–compulsive disorder. CNS Drugs 25(7):585–596 CrossRefPubMed Abudy A, Juven-Wetzler A, Zohar J (2011) Pharmacological management of treatment-resistant obsessive–compulsive disorder. CNS Drugs 25(7):585–596 CrossRefPubMed
18.
go back to reference Fontenelle LF et al (2007) An update on the pharmacological treatment of obsessive–compulsive disorder. Expert Opin Pharmacother 8(5):563–583 CrossRefPubMed Fontenelle LF et al (2007) An update on the pharmacological treatment of obsessive–compulsive disorder. Expert Opin Pharmacother 8(5):563–583 CrossRefPubMed
19.
go back to reference Skapinakis P, Papatheodorou T, Mavreas V (2007) Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive–compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 17(2):79–93 CrossRefPubMed Skapinakis P, Papatheodorou T, Mavreas V (2007) Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive–compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 17(2):79–93 CrossRefPubMed
20.
go back to reference DeLeon A, Patel NC, Crismon ML (2004) Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26(5):649–666 CrossRefPubMed DeLeon A, Patel NC, Crismon ML (2004) Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26(5):649–666 CrossRefPubMed
21.
go back to reference Matsunaga H et al (2011) A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder. Int J Psychiatry Clin Pract 15(4):263–269 CrossRefPubMed Matsunaga H et al (2011) A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder. Int J Psychiatry Clin Pract 15(4):263–269 CrossRefPubMed
22.
go back to reference Higuma H et al (2012) Aripiprazole augmentation in 13 patients with refractory obsessive–compulsive disorder: a case series. World J Biol Psychiatry 13(1):14–21 CrossRefPubMed Higuma H et al (2012) Aripiprazole augmentation in 13 patients with refractory obsessive–compulsive disorder: a case series. World J Biol Psychiatry 13(1):14–21 CrossRefPubMed
23.
go back to reference Muscatello MR et al (2011) Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 31(2):174–179 CrossRefPubMed Muscatello MR et al (2011) Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 31(2):174–179 CrossRefPubMed
24.
go back to reference Sayyah M et al (2012) Effects of aripiprazole augmentation in treatment-resistant obsessive–compulsive disorder (a double blind clinical trial). Depress Anxiety 29(10):850–854 CrossRefPubMed Sayyah M et al (2012) Effects of aripiprazole augmentation in treatment-resistant obsessive–compulsive disorder (a double blind clinical trial). Depress Anxiety 29(10):850–854 CrossRefPubMed
25.
go back to reference Masi G et al (2010) Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive–compulsive disorder. J Clin Psychopharmacol 30(6):688–693 CrossRefPubMed Masi G et al (2010) Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive–compulsive disorder. J Clin Psychopharmacol 30(6):688–693 CrossRefPubMed
26.
go back to reference Ercan ES et al (2015) A promising preliminary study of aripiprazole for treatment-resistant childhood obsessive–compulsive disorder. J Child Adolesc Psychopharmacol 25(7):580–584 CrossRefPubMed Ercan ES et al (2015) A promising preliminary study of aripiprazole for treatment-resistant childhood obsessive–compulsive disorder. J Child Adolesc Psychopharmacol 25(7):580–584 CrossRefPubMed
27.
go back to reference APA (2000) Diagnostic and statistical manual of mental disorders, 4th edn, text revision. American Psychiatric Association, Washington APA (2000) Diagnostic and statistical manual of mental disorders, 4th edn, text revision. American Psychiatric Association, Washington
28.
go back to reference Gökler B et al (2004) Reliability and validity of schedule for affective disorders and schizophrenia for school age children-present and lifetime version-Turkish version (K-SADS-PL-T). Turk J Child Adolesc Health 11(3):109–116 Gökler B et al (2004) Reliability and validity of schedule for affective disorders and schizophrenia for school age children-present and lifetime version-Turkish version (K-SADS-PL-T). Turk J Child Adolesc Health 11(3):109–116
29.
go back to reference Scahill L et al (1997) Children’s Yale-Brown obsessive compulsive scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 36(6):844–852 CrossRefPubMed Scahill L et al (1997) Children’s Yale-Brown obsessive compulsive scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 36(6):844–852 CrossRefPubMed
30.
go back to reference Yucelen AG et al (2006) Interrater reliability and clinical efficacy of Children’s Yale-Brown obsessive–compulsive scale in an outpatient setting. Compr Psychiatry 47(1):48–53 CrossRefPubMed Yucelen AG et al (2006) Interrater reliability and clinical efficacy of Children’s Yale-Brown obsessive–compulsive scale in an outpatient setting. Compr Psychiatry 47(1):48–53 CrossRefPubMed
31.
go back to reference Guy W (1976) ECDEU assessment manual for psychopharmacology. US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, Rockville Guy W (1976) ECDEU assessment manual for psychopharmacology. US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration, Rockville
32.
go back to reference Bollini P et al (1999) Effectiveness of antidepressants. Meta-analysis of dose–effect relationships in randomised clinical trials. Br J Psychiatry 174:297–303 CrossRefPubMed Bollini P et al (1999) Effectiveness of antidepressants. Meta-analysis of dose–effect relationships in randomised clinical trials. Br J Psychiatry 174:297–303 CrossRefPubMed
33.
go back to reference National Institute for Health and Clinical Excellence: guidance. Obsessive–compulsive disorder: core interventions in the treatment of obsessive–compulsive disorder and body dysmorphic disorder, 2006. National Institute for Health and Clinical Excellence: guidance. Obsessive–compulsive disorder: core interventions in the treatment of obsessive–compulsive disorder and body dysmorphic disorder, 2006.
34.
go back to reference Fonseka TM, Muller DJ, Kennedy SH (2016) Inflammatory cytokines and antipsychotic-induced weight gain: review and clinical implications. Mol Neuropsychiatry 2(1):1–14 CrossRefPubMedPubMedCentral Fonseka TM, Muller DJ, Kennedy SH (2016) Inflammatory cytokines and antipsychotic-induced weight gain: review and clinical implications. Mol Neuropsychiatry 2(1):1–14 CrossRefPubMedPubMedCentral
35.
go back to reference Findling RL et al (2009) Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 70(10):1441–1451 CrossRefPubMed Findling RL et al (2009) Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 70(10):1441–1451 CrossRefPubMed
36.
go back to reference Bobo WV et al (2013) Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. J Am Med Assoc Psychiatry 70(10):1067–1075 Bobo WV et al (2013) Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. J Am Med Assoc Psychiatry 70(10):1067–1075
37.
go back to reference Hirsch LE, Pringsheim T (2016) Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 6:CD009043 Hirsch LE, Pringsheim T (2016) Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 6:CD009043
38.
go back to reference Connor KM et al (2005) The use of aripiprazole in obsessive–compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66(1):49–51 CrossRefPubMed Connor KM et al (2005) The use of aripiprazole in obsessive–compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66(1):49–51 CrossRefPubMed
39.
go back to reference Storch EA et al (2008) Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive–compulsive disorder. Depress Anxiety 25(2):172–174 CrossRefPubMed Storch EA et al (2008) Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive–compulsive disorder. Depress Anxiety 25(2):172–174 CrossRefPubMed
40.
go back to reference Sarkar R, Klein J, Kruger S (2008) Aripiprazole augmentation in treatment-refractory obsessive–compulsive disorder. Psychopharmacology (Berl) 197(4):687–688 CrossRef Sarkar R, Klein J, Kruger S (2008) Aripiprazole augmentation in treatment-refractory obsessive–compulsive disorder. Psychopharmacology (Berl) 197(4):687–688 CrossRef
Metagegevens
Titel
Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive–Compulsive Disorder in Childhood
Auteurs
Ulku Akyol Ardic
Eyup Sabri Ercan
Ayse Kutlu
Deniz Yuce
Melis Ipci
Sevim Berrin Inci
Publicatiedatum
03-11-2016
Uitgeverij
Springer US
Gepubliceerd in
Child Psychiatry & Human Development / Uitgave 5/2017
Print ISSN: 0009-398X
Elektronisch ISSN: 1573-3327
DOI
https://doi.org/10.1007/s10578-016-0694-8